Waiv

The AI engine Fit Assessment

Beta

Owkin effectively utilizes machine learning to discover patterns, expand therapeutics, and identify biomarkers, enhancing personalized medicine.

Blurb

Developer of machine learning tools designed to augment medical and biological research. The company's platform understands complex biology through AI, identifies new treatments, de-risk, and accelerates clinical trials to inform drug discovery, de-risk clinical trials, and develop and deploy diagnostics, enabling pharmaceutical companies to understand drug efficacy variation, to improve the drug development process, and improve treatment outcomes.

HQ Location

New York (United States)

Founded

2016

Employees

201 - 500

Total funding raised

$337.10M

Funding Status

Venture - Series Unknown, $33.00M, March 12, 2026
Subspaces
  • Biomarker Identification

Owkin is building the first BASI to unlock breakthroughs in therapies, diagnostics, and rejuvenation, while reshaping how humanity understands and engineers biology.



Like other frontier AI companies, we believe the leap from narrow tools to true reasoning systems marks the start of a new era — where intelligence is not just assisting scientists but autonomously advancing discovery.

Owkin’s moats are structural and compounding. We are creating the only large-scale reasoning model trained natively on patient-level multimodal data and reinforced through real biological feedback — a closed-loop system that continuously improves itself. Exclusive partnerships with world-class hospitals, unique longitudinal datasets, and automated lab infrastructure create a defensibility flywheel similar to the data moats seen in other generational AI companies. By uniting reasoning models, agentic workflows, and living biological systems, Owkin is building the operating system for biology — a platform no one else can replicate, and the inevitable leader in general-purpose biology intelligence.